UNSPSC 51281663: Paromomycin sulfate

This classification denotes an aminoglycoside antibiotic with the molecular formula C23H45N5O14.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 845NU6GJPS, chemically known as o-2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl-(1->3)-o-beta-d-ribofuranosyl-(1->5)-o-(2-amino-2-deoxy-alpha-d-glucopyranosyl-(1->4))-2-deoxystreptamine sulfate (salt) but more generally known as paromomycin sulfate, which bears US NIH Compound Identifier 64144.

UNSPSC 51281663 Paromomycin sulfate is a Commodity code that catalogues a specific antibiotic pharmaceutical product; however, the recent state and local contract opportunities on record show little relevant purchasing activity under this code. The two most recent opportunities posted in the database — an Illinois Department of Public Health pharmaceutical warehouse piggyback contract and a Seminole County, Florida procurement for naloxone and drug deactivation systems — involve different pharmaceutical products entirely (doxycycline hyclate, ciprofloxacin hydrochloride, and naloxone) and do not reflect procurement of paromomycin sulfate itself. State and local health departments and counties do solicit pharmaceutical supplies through cooperative purchasing vehicles such as MMCAP Infuse and direct IFB processes, but the code's narrow scope to a single active pharmaceutical ingredient means activity here depends on specific, episodic public-health demand for paromomycin treatment protocols.

Without documented recent solicitations targeting paromomycin sulfate specifically, geographic concentration and representative opportunities cannot be reliably characterized from this source. Vendors pursuing this code should monitor state health department emergency preparedness and communicable-disease procurement channels — particularly in states with active tropical-disease or parasitic-infection treatment programs — and track cooperative purchasing schedules that may bundle paromomycin into broader pharmaceutical warehousing contracts, though such bundling has not appeared in recent postings.